Sickle cell disease--pathophysiology and treatment.
Redding-Lallinger
Rupa
R
Division of Hematology/Oncology, Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.
Knoll
Christine
C
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use; D000755:Anemia, Sickle Cell / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D019072:Antibiotic Prophylaxis; D000986:Antisickling Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D005260:Female; D005838:Genotype; D018380:Hematopoietic Stem Cell Transplantation; D006760:Hospitalization; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use; D007052:Ibuprofen / Q000008:administration & dosage / Q000627:therapeutic use; D007114:Immunization; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000627:therapeutic use; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D010147:Pain Measurement; D010406:Penicillins / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D000701:Analgesics, Opioid; D000986:Antisickling Agents; D010406:Penicillins; D009020:Morphine; D007052:Ibuprofen; D006918:Hydroxyurea